Trial Profile

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Nov 2025 According to the Novo Nordisk Media Release, based on results from this trial the company submitted sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity.Under the CNPV expedited program, review is expected within 1-2 months following the FDAs acceptance of the filing.
20 Oct 2025 According to the Novo Nordisk Media Release, data will be presented at ObesityWeek from 4-7 November in Atlanta, US.
05 Sep 2025 According to a Novo Nordisk Media Release, data from this trial will be presented at association for the Study of Diabetes (EASD) congress 2025 from 15 to 19 September in Vienna, Austria

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com